ImmunotherapyPreventative VaccinesGene Therapy

Etubics

Welcome to Etubics

Etubics Corporation is a Seattle based biopharmaceutical company developing targeted immunotherapies and vaccine products for a wide range of resilient diseases. Etubics patent-protected technology has been proven to be safer, more efficient and more effective than current vectored vaccines and gene delivery platforms.

We specialize in developing innovative immunotherapies and vaccines utilizing our exclusive next-generation viral vector gene delivery technology and our patented manufacturing cell line, together the Etubics Platform.

The Etubics Platform delivers a long lasting “active” immune response against diseases and induces both cell mediated immunity and antibody. The Etubics Platform provides the following capabilities:

  • Utilization of boosting
  • Enhanced CMI response
  • No unwanted viral replication in the body
  • Treatment of multiple diseases in the same patient
  • Convenient subcutaneous injection
Next Generation Vaccines What’s New

Etubics is developing innovative immunotherapies and vaccines, utilizing our proprietary gene delivery platform and our patented human E.C7 human cell line, together the Etubics Platform.

The Etubics Platform provides the following capabilities: a long lasting “active” immune response against diseases and induces both cell mediated immunity and antibody.

Find out more about our Technology

Etubics enters into a CRADA with the National Cancer Institute

Etubics Corporation has signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute, a part of the National Institutes of Health, to investigate a multi-targeted immunotherapy approach containing three tumor-associated antigens including ETBX-011. These three antigens are highly expressed in various human carcinomas and the ability to simultaneously target all three could be of significant clinical benefit in terms of overall survival of cancer patients.

Cancer Immunology, Immunotherapy has published Etubics’ article entitled “Extended evaluation of a Phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late stage colorectal cancer.”

This article reports extended observations on long-term overall survival and additional immune analyses of late stage colorectal cancer patients treated with Etubics immunotherapeutic ETBX-011.  The article is available at SpringerLink.

vaccine2

Last Updated: July 2015